Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420653 · ClinicalTrials.gov registry record · Phase 3
Maxigesic 325 Acute Dental Pain Study
A Phase 3 study, sponsored by AFT Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT01420653 is a Phase 3 study that has completed, run by AFT Pharmaceuticals. The registered enrollment target is 408 participants.
The verdict
NCT01420653, a Phase 3 study, has completed, sponsored by AFT Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.
Interventions
- DRUG Placebo
- DRUG Acetaminophen
- DRUG Ibuprofen
- DRUG Maxigesic 325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420653
The ClinicalTrials.gov registry entry for NCT01420653 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AFT Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01420653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01420653 about?
NCT01420653 is a clinical study titled "Maxigesic 325 Acute Dental Pain Study". The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.
What is the current status of trial NCT01420653?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2013-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01420653?
The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), Ibuprofen (DRUG), Maxigesic 325 (DRUG).
Who is sponsoring clinical trial NCT01420653?
This trial is sponsored by AFT Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.